Triple-Drug KRAS Attack Erases Pancreatic Tumors in Mice

CNIO researchers report a triple-drug regimen that blocks the KRAS signaling pathway at three points—using daraxonrasib, afatinib, and SD36—to induce durable tumor regression and prevent resistance in three mouse models of pancreatic ductal adenocarcinoma (PDAC) with minimal toxicity. While promising, they caution that the approach is not yet ready for clinical trials and would require further development to adapt for human use, per the PNAS study.